ALK and non-small cell lung carcinoma: Ceritinib as second- or later-line therapy is recommended for ALK+ NSCLC patients with resistance to or progression after treatment with first-line ALK-tyrosine kinase inhibitors (PS 0–2; recommendation grade 2C).